Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1

24-week results of the phase III VIKING-3 study

Antonella Castagna, Franco Maggiolo, Giovanni Penco, David Wright, Anthony Mills, Robert Grossberg, Jean Michel Molina, Julie Chas, Jacques Durant, Santiago Moreno, Manuela Doroana, Mounir Ait-Khaled, Jenny Huang, Sherene Min, Ivy Song, Cindy Vavro, Garrett Nichols, Jane M. Yeo

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA

Original languageEnglish
Pages (from-to)354-362
Number of pages9
JournalJournal of Infectious Diseases
Volume210
Issue number3
DOIs
Publication statusPublished - Aug 1 2014

Fingerprint

Integrase Inhibitors
HIV-1
RNA
HIV
Viruses
Pharmaceutical Preparations
dolutegravir
JTK 303
Raltegravir Potassium
Therapeutics

Keywords

  • Dolutegravir
  • DTG
  • Elvitegravir resistance
  • Integrase inhibitor
  • Raltegravir resistance

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1 : 24-week results of the phase III VIKING-3 study. / Castagna, Antonella; Maggiolo, Franco; Penco, Giovanni; Wright, David; Mills, Anthony; Grossberg, Robert; Molina, Jean Michel; Chas, Julie; Durant, Jacques; Moreno, Santiago; Doroana, Manuela; Ait-Khaled, Mounir; Huang, Jenny; Min, Sherene; Song, Ivy; Vavro, Cindy; Nichols, Garrett; Yeo, Jane M.

In: Journal of Infectious Diseases, Vol. 210, No. 3, 01.08.2014, p. 354-362.

Research output: Contribution to journalArticle

Castagna, A, Maggiolo, F, Penco, G, Wright, D, Mills, A, Grossberg, R, Molina, JM, Chas, J, Durant, J, Moreno, S, Doroana, M, Ait-Khaled, M, Huang, J, Min, S, Song, I, Vavro, C, Nichols, G & Yeo, JM 2014, 'Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study', Journal of Infectious Diseases, vol. 210, no. 3, pp. 354-362. https://doi.org/10.1093/infdis/jiu051
Castagna, Antonella ; Maggiolo, Franco ; Penco, Giovanni ; Wright, David ; Mills, Anthony ; Grossberg, Robert ; Molina, Jean Michel ; Chas, Julie ; Durant, Jacques ; Moreno, Santiago ; Doroana, Manuela ; Ait-Khaled, Mounir ; Huang, Jenny ; Min, Sherene ; Song, Ivy ; Vavro, Cindy ; Nichols, Garrett ; Yeo, Jane M. / Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1 : 24-week results of the phase III VIKING-3 study. In: Journal of Infectious Diseases. 2014 ; Vol. 210, No. 3. pp. 354-362.
@article{32eddcb12cf4413bb2548e27cc4ef0fc,
title = "Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study",
abstract = "Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA",
keywords = "Dolutegravir, DTG, Elvitegravir resistance, Integrase inhibitor, Raltegravir resistance",
author = "Antonella Castagna and Franco Maggiolo and Giovanni Penco and David Wright and Anthony Mills and Robert Grossberg and Molina, {Jean Michel} and Julie Chas and Jacques Durant and Santiago Moreno and Manuela Doroana and Mounir Ait-Khaled and Jenny Huang and Sherene Min and Ivy Song and Cindy Vavro and Garrett Nichols and Yeo, {Jane M.}",
year = "2014",
month = "8",
day = "1",
doi = "10.1093/infdis/jiu051",
language = "English",
volume = "210",
pages = "354--362",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1

T2 - 24-week results of the phase III VIKING-3 study

AU - Castagna, Antonella

AU - Maggiolo, Franco

AU - Penco, Giovanni

AU - Wright, David

AU - Mills, Anthony

AU - Grossberg, Robert

AU - Molina, Jean Michel

AU - Chas, Julie

AU - Durant, Jacques

AU - Moreno, Santiago

AU - Doroana, Manuela

AU - Ait-Khaled, Mounir

AU - Huang, Jenny

AU - Min, Sherene

AU - Song, Ivy

AU - Vavro, Cindy

AU - Nichols, Garrett

AU - Yeo, Jane M.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA

AB - Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA

KW - Dolutegravir

KW - DTG

KW - Elvitegravir resistance

KW - Integrase inhibitor

KW - Raltegravir resistance

UR - http://www.scopus.com/inward/record.url?scp=84898987717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898987717&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiu051

DO - 10.1093/infdis/jiu051

M3 - Article

VL - 210

SP - 354

EP - 362

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -